topic

335 Novel coupledCARTM technology for treating colorectal cancer
Song Li, Chengfei Pu, Zhiyuan Cao, Ning Li, Xinyi Yang, Youli Luo, Haiyan Zhao, Hang Yang, Xi Huang, Xiaogang Shen, Xiuwen Wang, Yongping Song, Junjie Mao, Pengfei Pang, Qun Hu, Zhao Wu, Lei Xiao

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A205; DOI: 10.1136/jitc-2020-SITC2020.0335
338 Emerging insights on the association of tumor molecular phenotype with clinical benefit in metastatic colorectal cancer (mCRC) subjects treated with AB928 + modified FOLFOX-6 (mFOLFOX-6)
Akshata Udyavar, Michael Cecchini, Daniel DiRenzo, Sean Cho, Lisa Seitz, Kristen Zhang, Stephen Young, Amy Anderson, Kimberline Gerrick, Matthew Walters, Houston Gilbert, Olivia Gardner, Cheng Quah, Juan Jaen, William Grossman

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A206-A207; DOI: 10.1136/jitc-2020-SITC2020.0338
339 Preliminary safety, tolerability and efficacy results of KN026 (a HER2-targeted Bispecific Antibody) in combination with KN046 (an anti-PD-L1/CTLA-4 Bispecific Antibody) in patients (pts) with HER2 aberrated solid tumors
Jifang Gong, Zhi Dong, Dan Liu, June Xu, Jing Yang, Yue Yang, Yakun Qi, Jie Men, Paul Kong, Ting Xu, Lin Shen

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A207; DOI: 10.1136/jitc-2020-SITC2020.0339
342 A phase 3 study (COSMIC-313) of cabozantinib in combination with nivolumab and ipilimumab in patients with previously untreated advanced renal cell carcinoma of intermediate or poor risk
Toni Choueiri, Laurence Albiges, Thomas Powles, Nehal Mohamed, Fong Wang, Robert Motzer

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A209; DOI: 10.1136/jitc-2020-SITC2020.0342
348 A phase 2 umbrella study of retifanlimab (INCMGA00012) alone or in combination with other therapies in patients with advanced or metastatic endometrial cancer (POD1UM-204, GOG 3038, ENGOT-en12/NOGGO)
Brian Slomovitz, Bradley Monk, Katherine Moxley, Nadeem Ghali, Justyna Fronczek Sokol, Chuan Tian, Nawel Bourayou, Jalid Sehouli

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A212-A213; DOI: 10.1136/jitc-2020-SITC2020.0348
37 Monitoring the evolution of inflammatory bowel disease (IBD) in pediatric and adult cohorts of patients to identify biomarkers to predict cancer risk
Shilpa Ravindran, Heba Sidahmed, Harshitha Manjunath, Rebecca Mathew, Tanwir Habib, William Mifsud, Adrian Charles, Adham Ammar, Muhammad Khan, Saad Al-Kaabi, Anthony Akobeng, Muneera Al-Mohannadi, Mamoun Elawad, Sara Tomei, Cristina Maccalli

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A22; DOI: 10.1136/jitc-2020-SITC2020.0037
360 A phase 1 study of an Off-the-Shelf, multi-neoantigen vector (ADXS-503) alone and in combination with pembrolizumab in subjects with metastatic non-small cell lung cancer (NSCLC)
Jonathan Goldman, Thomas Stinchcombe, Gregory Gerstner, Missak Haigentz, Surya Vangala, Megan Parsi, Victor Kabala, Dinesh Simkhada, Andres Gutierrez, Suresh Ramalingam

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A220; DOI: 10.1136/jitc-2020-SITC2020.0360
362 A PhII study of bemcentinib, a first-in-class selective AXL kinase inhibitor, in combination with pembrolizumab in pts with previously-treated advanced NSCLC: Updated clinical & translational analysis
James Spicer, Åslaug Helland, Enric Carcereny, Edurne Arriola, Manuel Dómine Gomez, Jose Manuel Trigo Perez, Jonathan Thompson, James Strauss, Ana Laura Ortega Granados, Enriqueta Felip, Emmett Schmidt, Michael Chisamore, Noelly Madeleine, Austin Rayford, Katherine Lorens, Abdul Siddiqui, Hani Gabra, Jaya Nautiyal, David Micklem, James Lorens, Matthew Krebs

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A221; DOI: 10.1136/jitc-2020-SITC2020.0362
364 A personal neoantigen vaccine NEO-PV-01 in combination with chemotherapy and pembrolizumab induces broad de novo immune responses in first line, non-squamous NSCLC
Mark Awad, David Spigel, Edward Garon, Saiama Waqar, Aaron Lisberg, Melissa Moles, Jennifer Tepper, April Lamb, Amy Wanamaker, Zakaria Khondker, John Srouji, Jesse Dong, Asaf Poran, Kristen Balogh, Meghan Bushway, Mark DeMario, Lakshmi Srinivasan, Richard Gaynor, Ramaswamy Govindan

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A222; DOI: 10.1136/jitc-2020-SITC2020.0364
363 Vactosertib and durvalumab as second or later line treatment for PD-L1 positive non-small cell lung cancer: interim result
Byoung Chul Cho, Ki Hyeong Lee, Ji-Youn Han, Byoung Yong Shim, Hye Ryun Kim, Kyoung-Ho Pyo, Jae-Hwan Kim, Chung-Feng Xin, Jin Kyung Lee, Jiyeon Ryu, Bitna Oh, Sunjin Hwang, Ki Baik Hahm, Seong-Jin Kim

Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A222; DOI: 10.1136/jitc-2020-SITC2020.0363

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages